Continuous tralokinumab treatment over 4 years in adults with moderate-to-severe atopic dermatitis provides long-term disease control

被引：1
|
作者：
Blauvelt, Andrew [1 ]
Langley, Richard G. [2 ]
Peris, Ketty [3 ]
Silvestre, Juan Francisco [4 ]
Katoh, Norito [5 ]
Tauber, Marie [6 ,7 ]
Pinter, Andreas [8 ]
Ameen, Mahreen [9 ]
Gooderham, Melinda [10 ,11 ]
Oland, Christian Bjerregard [12 ]
Tindberg, Ann-Marie [12 ]
Gjerum, Le [12 ]
Reich, Kristian [13 ]
机构：
[1] Oregon Med Res Ctr, Portland, OR USA
[2] Dalhousie Univ, Div Clin Dermatol & Cutaneous Sci, Halifax, NS, Canada
[3] Univ Cattolica Sacro Cuore, Dermatol, Rome, Italy
[4] Hosp Gen Univ Dr Balmis, Dermatol Dept, ISABIAL, Alicante, Spain
[5] Kyoto Prefectural Univ Med, Grad Sch Med Sci, Kyoto, Japan
[6] Lyon Sud Hosp, Dept Allergol & Clin Immunol, Lyon, France
[7] INSERM, CIRI, U1111, Lyon, France
[8] Goethe Univ Frankfurt Main, Dept Dermatol Venereol & Allergol, Frankfurt, Germany
[9] Royal Free London Natl Hlth Serv Fdn Trust, London, England
[10] SKiN Ctr Dermatol, Peterborough, ON, Canada
[11] Queens Univ, Dept Dermatol, Kingston, ON, Canada
[12] LEO Pharma AS, Ballerup, Denmark
[13] Univ Med Ctr Hamburg Eppendorf, Inst Hlth Serv Res Dermatol & Nursing, Translat Res Inflammatory Skin Dis, Hamburg, Germany
来源：
BRITISH JOURNAL OF DERMATOLOGY | 2024年 / 190卷
关键词：
long-term; efficacy; ECZTEND; tralokinumab; moderate-to-severe;
D O I：
10.1093/bjd/ljad498.050
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
551
引用
收藏
页码：II48 / II49
页数：2
相关论文
共 50 条
  • [21] Long-term efficacy, safety, and adherence to tralokinumab treatment in moderate-to-severe atopic dermatitis for up to 3 years: Interim readout of ECZTEND, a phase 3, long-term extension trial
    Blauvelt, Andrew
    Lacour, Jean-Philippe
    Toth, Darryl
    Laquer, Vivian
    Beissert, Stefan
    Wollenberg, Andreas
    Herranz, Pedro
    Pink, Andrew
    Peris, Ketty
    Saeki, Hidehisa
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2021, 85 (03) : AB159 - AB159
  • [22] Dupilumab Treatment in Adults with Moderate-to-Severe Atopic Dermatitis
    Beck, Lisa A.
    Thaci, Diamant
    Hamilton, Jennifer D.
    Graham, Neil M.
    Bieber, Thomas
    Rocklin, Ross
    Ming, Jeffrey E.
    Ren, Haobo
    Kao, Richard
    Simpson, Eric
    Ardeleanu, Marius
    Weinstein, Steven P.
    Pirozzi, Gianluca
    Guttman-Yassky, Emma
    Suarez-Farinas, Mayte
    Hager, Melissa D.
    Stahl, Neil
    Yancopoulos, George D.
    Radin, Allen R.
    NEW ENGLAND JOURNAL OF MEDICINE, 2014, 371 (02): : 130 - 139
  • [23] Long-term dupilumab treatment is not associated with an increased overall risk of infections in adults with moderate-to-severe atopic dermatitis
    Beck, Lisa A.
    Simpson, Eric L.
    Thaci, Diamant
    de Bruin-Weller, Marjolein
    Deleuran, Mette
    Kataoka, Yoko
    Friedman, Adam J.
    Khokhar, Faisal A.
    Coleman, Anna
    Gherardi, Guy
    Chen, Zhen
    Avetisova, Elena
    Zhang, Annie
    Nguyen, Tien, V
    BRITISH JOURNAL OF DERMATOLOGY, 2024, 191 : 71 - 72
  • [24] Patient wellbeing and perception of treatment effect with long-term dupilumab monotherapy in adults with moderate-to-severe atopic dermatitis
    Simpson, E. L.
    Beissert, S.
    Beck, L. A.
    Zhang, H.
    Aamodt, K.
    Rossi, A. B.
    BRITISH JOURNAL OF DERMATOLOGY, 2022, 186 (04) : E139 - E139
  • [25] Long-term treatment with dupilumab minimizes use of systemic immunosuppressants as rescue medications in adults with moderate-to-severe atopic dermatitis
    Beck, L. A.
    Blauvelt, A.
    Sher, L.
    Hussain, I.
    Rossi, A. B.
    Chen, Z.
    Shumel, B.
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2020, 140 (07) : S53 - S53
  • [26] Emerging Role of Atopic Dermatitis Control Tool in Long-Term Monitoring of Patients With Moderate-to-Severe Atopic Dermatitis Treated With Dupilumab
    Cioppa, Vittoria
    Lazzeri, Laura
    Carraro, Andrea
    De Piano, Ernesto
    Falcinelli, Francesca
    Galluzzo, Marco
    Pallotta, Sabatino
    De Pita, Ornella
    Russo, Filomena
    DERMATITIS, 2024, 35
  • [27] LONG-TERM SAFETY DATA FOR DUPILUMAB UP TO 4 YEARS IN AN OPEN-LABEL EXTENSION STUDY OF ADULTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS
    Wollenberg, Andreas
    Deleuran, Mette
    Soong, Weily
    Gooderham, Melinda
    Bissonnette, Robert
    Xiao, Jing
    Khokhar, Faisal A.
    Levit, Noah A.
    Rodriguez Marco, Ainara
    Shabbir, Arsalan
    ACTA DERMATO-VENEREOLOGICA, 2022, 102 : 34 - 35
  • [28] Long-term safety data for dupilumab up to 4 years in an open-label extension study of adults with moderate-to-severe atopic dermatitis
    Wollenberg, A.
    Soong, W.
    Goooderham, M.
    Bissonnette, R.
    Xiao, J.
    Khokhar, F. A.
    Marco, A. R.
    Levit, N. A.
    Shabbir, A.
    BRITISH JOURNAL OF DERMATOLOGY, 2022, 186 (04) : E163 - E163
  • [29] Long-term safety data for dupilumab up to 4 years in an open-label extension study of adults with moderate-to-severe atopic dermatitis
    Gooderham, Melinda
    Wollenberg, Andreas
    Soong, Weily
    Bissonnette, Robert
    Xiao, Jing
    Khokhar, Faisal A.
    Marco, Ainara Rodriguez
    Levit, Noah A.
    Shabbir, Arsalan
    ALLERGY AND ASTHMA PROCEEDINGS, 2022, 43 (06) : 561 - 561
  • [30] Advances in Systemic Treatment for Adults With Moderate-to-Severe Atopic Dermatitis
    Cho, Yung-Tsu
    Chu, Chia-Yu
    DERMATOLOGICA SINICA, 2019, 37 (01) : 3 - 11
12345